Hospira seeks FDA nod for Epogen/Procrit biosimilar
This article was originally published in Scrip
Executive Summary
On 12 January, Hospira became the fourth company in the US to disclose it had submitted a so-called 351(k) biosimilar biological product application to the FDA – following other firms Sandoz, Celltrion and Apotex.